Hydroxyurea and Transfusion Combined Improve Severe Sickle Cell Disease Treatment
A recent study published in the Annals of Translational Medicine highlights the benefits of combining hydroxyurea and blood transfusion therapies for patients with severe sickle cell disease. This combination approach marks a significant advancement in defining effective treatment strategies, potentially improving patient outcomes by addressing the disease more comprehensively than either therapy alone.
Annals of Translational Medicine·


